Loading company
Quoin Pharmaceuticals Ltd.
QNRX · Nasdaq · ·
Next earnings: November 5, 2026
$5.68-11.7%Sep 28 close
- 1M
- -7.3%
- 6M
- -9.6%
- 1Y
- -21.1%
- 5Y
- -100.0%
QNRX · Nasdaq · ·
Next earnings: November 5, 2026
$5.68-11.7%Sep 28 close
Quoin Pharmaceuticals Ltd. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$5.4M | -$3.7M | -45.32% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Quoin Pharmaceuticals Ltd. has no earnings call transcript available.
“The second quarter was a highly productive period across both of our delivery technology platforms,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin’s innovative pipeline is focused on two key platform products, QRX003 and QRX009, that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, microcystic lymphatic malformations, venous malformations, angiofibromas and others.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Quoin Pharmaceuticals Ltd.’s Item 2.02 8-K filed August 14, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.